京东健康与翰森制药深化合作 打造药品全链路数字化通路

Core Insights - JD Health and Hansoh Pharmaceutical are deepening their collaboration, with Hansoh's new pulmonary hypertension drug, Silapad, set for exclusive online launch on JD Health's platform [1][3] - The partnership aims to enhance drug accessibility for pulmonary hypertension patients and leverage JD Health's channel advantages for market coverage [1][3] Summary by Sections Collaboration Details - The collaboration will expand into multiple fields, including anti-infection and respiratory health, with JD Health enhancing patient medication adherence through professional services [3] - In the second half of 2025, Hansoh will deepen cooperation in metabolism and oncology areas on JD Health's platform [3] Product Launch and Services - Hansoh plans to launch more core products on JD's self-operated channels, prioritizing innovative drugs for exclusive online release [3] - The partnership will create a closed-loop service from online consultations to drug delivery, utilizing JD's internet hospital and pharmacy capabilities [3] Strategic Importance - Hansoh's collaboration with JD Health is a key part of its strategic transformation, aiming to manage the full cycle from product development to patient service [3] - Both companies emphasize the importance of patient needs and aim to improve the accessibility of innovative drugs and comprehensive health management solutions [3]